Freeman Technology relocates to larger premises
New global hq includes manufacturing and office space and an applications laboratory
The new 6,000ft2 global headquarters has been equipped to meet the company’s requirements for manufacturing and office space, as well as housing a 300ft2 applications laboratory.
The move into this ultra-modern facility comes just over a decade after the company launched its first powder testing instrument.
Operations director Tim Freeman said: ‘I am delighted to be able to report that demand for the FT4 powder rheometer continues to grow around the world and across powder processing industries.
‘As a result, not only are we building more systems, but we are also continuing to invest in r&d and applications development.
‘This new facility will enable us to scale up our manufacturing and r&d operations and continue to expand well into the future.’
He said the new laboratory would enable the company to carry out additional in-house research into powder behaviour and processing and provide more extensive applications support for customers.
Freeman Technology has enjoyed a continued period of growth and success. This year the company has not only added to its UK-based team but also expanded its global distribution network, with new partnerships covering Japan, India, Singapore, Malaysia, Thailand and Taiwan.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Britain's biotech potential (part II): world-class science, second-class support?
Read moreIn part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Britain's biotech potential (part II): world-class science, second-class support?
In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Finance
Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach
The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Analysis
Introducing Shimadzu’s MultiNA II: Redefining precision in life science analysis
Designed with users in mind, the MultiNA II MCE-301 is a fully automated microchip electrophoresis system designed to accelerate and simplify genetic analysis workflows in pharmaceutical and biopharmaceutical laboratories
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Finance
UK biotech venture capital rises 17% in Q1 2026 as deal activity surges 67% year-on-year, BIA figures show
Total UK biotech equity financing reached £552m in the first quarter of 2026, driven by a 17% quarterly rise in venture capital investment, according to BioIndustry Association data, though public markets remain dormant with no IPOs recorded since 2022